Not necessarily wegian, this is a completely new management to the ones who purchased Medivet.
As for the price of Medivet, you would think that being US based and reaching out to VC over there they may be able to factor in a bit more blue sky to their valuations than what you generally find in the Aus market. Like I said in my previous post, I am comfortable working on $2-3m finding it's way back to MLA.
Also great post groberts. Sums up the situation very succinctly. I think most of your notes are positive, the only one that may cause some concern is the slip in 2H sales for Human Healthcare, but I agree we wait and see with the next report before making a decision.
MLA Price at posting:
5.0¢ Sentiment: Buy Disclosure: Held
